-Reuters
Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5
Cowen & Co. analyst Ritu Baral downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Market Perform and raises the price target from $67 to $68.5.